WuXi XDC Cayman Inc
2268
Rank in Stocks
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Share Price
$8.78
Market Cap
$11.12B
Change (1 day)
-9.52%
Change (1 year)
0.57%
Country
CN
Trade WuXi XDC Cayman Inc (2268)
Category
Healthcare
P/S ratio for WuXi XDC Cayman Inc (2268)
P/S ratio as of October 2026 TTM: 10.77
According to WuXi XDC Cayman Inc latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.77. At the end of 2024 the company had a P/S ratio of 8.51.
P/S ratio history for WuXi XDC Cayman Inc from 2020 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 10.77 | -11.24% |
| 2025 | 12.13 | 42.53% |
| 2024 | 8.51 | -42.82% |
| 2023 | 14.89 | -49.39% |
| 2022 | 29.42 | -65.94% |
| 2021 | 86.37 | -70.02% |
| 2020 | 288.11 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 5.37 | -50.10% |
US
|
|
| 6.29 | -41.56% |
US
|
|
| 21.02 | 95.24% |
US
|
|
| 6.53 | -39.37% |
CN
|
|
| 6.80 | -36.85% |
US
|
